In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Difference in n-terminal pro-b-type natriuretic peptide (NT-proBNP) levels in patients with heart failure with preserved ejection fraction (HFpEF) and non-cardiac comorbidity

Session Poster Session 2

Speaker Ekaterina Chernyaeva

Event : Heart Failure 2018

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure - Pathophysiology, Other
  • Session type : Poster Session

Authors : KI Cherniaieva (Kiev,UA)

Authors:
KI Cherniaieva1 , 1National O.O. Bohomolets Medical University, Department Internal Medicine - Kiev - Ukraine ,

Citation:

Multiple studies have already revealed a direct link between non-cardiac comorbidities and the development of HFpEF, emphasizing that it is challenging to assess how significant is a role of the comorbidities and their combinations in elevation of plasma NT-proBNP levels.

Purpose. To estimate the difference between NT-proBNP values in patients with HFpEF, who have one or more concomitant non-cardiac diseases diagnosed prior or during hospitalization, or doesn’t have any of them.

Materials and methods. We enrolled 80 hemodynamically stable patients with HFpEF, confirmed clinically (signs and symptoms), instrumentally (echocardiography with careful evaluation of left ventricle diastolic function) and laboratory (elevated plasma NT-proBNP level). After additional examination (plasma levels of glucose and HbAc1, hemoglobin, ferritin,  GFR, calculated by CKD-EPI  and spirometry) patients were divided into 4 groups: with 1, 2 or 3 and more concomitant non-cardiac diseases, or without them.

Results. Non-cardiac comorbidity was present in 57 (71,25%) patients. Group 1 included 22 patients (27,5%), Group 2 – 12 (15%), Group 3 – 23 (28,75%) and Group 4 – 13 (16,25%). They didn't differ in age (63,2±10,9 vs 63±6,9 vs 69,9±6,6 and 65±7,7 years), gender (12 (54,5%) vs 7 (58,3%) vs 10 (43,5%) and 8 (61,5%) males) and body mass index (30,9±4,3 vs 28,1±1,9 vs 30,9±4,1 and 28,8±2,7); all p>0,05. Plasma NT-pro-BNP levels are demonstrated in the table. The revealed comorbidities distributed following way: type 1 diabetes mellitus  – 23 (28,75%) patients, anemia – 16 (20%) patients, chronic renal impairment – 34 (42,5%), ventilation disorders  (obstructive,  restrictive and combined) – 29 (36,25%).

Conclusions: Benefits of using comorbidity-oriented approach to assessment of patients with HFpEF can be proven by statistically important difference in mean NT-proBNP levels between groups of patients with concomitant non-cardiac diseases and a group with none of them.  Combination of non-cardiac comorbidities, when 3 or more are present, can cause higher levels of NT-proBNP.

Gr1 (n=22)

M±m

Gr2 (n=12)

M±m

Gr3 (n=23)

M±m

Gr4 (n=13)

M±m

NT-proBNP 420,6±231,6* 615,4±323** 947,4±402,9*** 287,4±132,2
*p<0,001 compared to group 3; **p=0,012 compared to group 4; ***p<0,001 compared to group 4.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are